Acharya S, Hegde U, Acharya A, Nitin P
Heliyon. 2024; 10(11):e32259.
PMID: 38947439
PMC: 11214465.
DOI: 10.1016/j.heliyon.2024.e32259.
Wang W, Cao X, Bian L, Gao Y, Yu M, Li Y
BMC Cancer. 2023; 23(1):591.
PMID: 37365497
PMC: 10294399.
DOI: 10.1186/s12885-023-11028-5.
Dey Ghosh R, Guha Majumder S
Cancers (Basel). 2022; 14(22).
PMID: 36428681
PMC: 9688117.
DOI: 10.3390/cancers14225590.
Shitozawa Y, Haro K, Ogawa M, Miyawaki A, Saito M, Fukuda K
Sci Rep. 2022; 12(1):16839.
PMID: 36207390
PMC: 9546904.
DOI: 10.1038/s41598-022-21031-8.
Li S, Gao L, Liu J, Guo C, Zheng J, Zhi K
Cell Death Discov. 2022; 8(1):373.
PMID: 36008375
PMC: 9411559.
DOI: 10.1038/s41420-022-01168-1.
CD73 facilitates invadopodia formation and boosts malignancy of head and neck squamous cell carcinoma via the MAPK signaling pathway.
Xue F, Wang T, Shi H, Feng H, Feng G, Wang R
Cancer Sci. 2022; 113(8):2704-2715.
PMID: 35657703
PMC: 9357645.
DOI: 10.1111/cas.15452.
LINC00461 facilitates HNSCC development and reduces chemosensitivity by impairing miR-195-mediated inhibition of HOXA10.
Guan Y, Guan A, Chen L, Gong A
Mol Ther Oncolytics. 2021; 21:74-86.
PMID: 33869744
PMC: 8027536.
DOI: 10.1016/j.omto.2021.01.008.
Dysbiosis of Oral Microbiota During Oral Squamous Cell Carcinoma Development.
Sarkar P, Malik S, Laha S, Das S, Bunk S, Ray J
Front Oncol. 2021; 11:614448.
PMID: 33708627
PMC: 7940518.
DOI: 10.3389/fonc.2021.614448.
A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma.
Qi Z, Qiu Y, Wang Z, Zhang H, Lu L, Liu Y
Mol Oncol. 2021; 15(4):1054-1068.
PMID: 33540470
PMC: 8024719.
DOI: 10.1002/1878-0261.12919.
Functional Landscape of Dysregulated MicroRNAs in Oral Squamous Cell Carcinoma: Clinical Implications.
Dey Ghosh R, Pattatheyil A, Roychoudhury S
Front Oncol. 2020; 10:619.
PMID: 32547936
PMC: 7274490.
DOI: 10.3389/fonc.2020.00619.
The Oral Microbiota May Have Influence on Oral Cancer.
Zhang L, Liu Y, Zheng H, Zhang C
Front Cell Infect Microbiol. 2020; 9:476.
PMID: 32010645
PMC: 6974454.
DOI: 10.3389/fcimb.2019.00476.
Fog Computing Employed Computer Aided Cancer Classification System Using Deep Neural Network in Internet of Things Based Healthcare System.
Rajan J, Rajan S, Martis R, Panigrahi B
J Med Syst. 2019; 44(2):34.
PMID: 31853735
DOI: 10.1007/s10916-019-1500-5.
DNA methylation derived systemic inflammation indices are associated with head and neck cancer development and survival.
Ambatipudi S, Langdon R, Richmond R, Suderman M, Koestler D, Kelsey K
Oral Oncol. 2018; 85:87-94.
PMID: 30220325
PMC: 6156796.
DOI: 10.1016/j.oraloncology.2018.08.021.
Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging.
Yang C, Yeh Y, Yu H, Chin C, Hsu C, Liu H
Front Microbiol. 2018; 9:862.
PMID: 29774014
PMC: 5943489.
DOI: 10.3389/fmicb.2018.00862.
Epithelial-Mesenchymal Transition during Metastasis of HPV-Negative Pharyngeal Squamous Cell Carcinoma.
Ihler F, Gratz R, Wolff H, Weiss B, Bertlich M, Kitz J
Biomed Res Int. 2018; 2018:7929104.
PMID: 29693014
PMC: 5859914.
DOI: 10.1155/2018/7929104.
Recipient Vessel Selection in Head and Neck Reconstruction.
Hiller A, Davis J, Schulz S, Henderson J, Wilhelmi B
Eplasty. 2018; 17:e42.
PMID: 29348784
PMC: 5749370.
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
Shayan G, Kansy B, Gibson S, Srivastava R, Bryan J, Bauman J
Clin Cancer Res. 2017; 24(1):62-72.
PMID: 29061643
PMC: 5754237.
DOI: 10.1158/1078-0432.CCR-17-0357.
Survivorship of patients with head and neck cancer receiving care in a tertiary health facility in Nigeria.
Okwor V, Fagbamigbe A, Fawole O
Cancer Manag Res. 2017; 9:331-338.
PMID: 28790865
PMC: 5531721.
DOI: 10.2147/CMAR.S133108.
Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial.
Arnold S, Kudrimoti M, Dressler E, Gleason Jr J, Silver N, Regine W
Adv Radiat Oncol. 2017; 1(4):252-259.
PMID: 28740895
PMC: 5514161.
DOI: 10.1016/j.adro.2016.06.003.
p16, HPV, and Cetuximab: What Is the Evidence?.
Bonner J, Mesia R, Giralt J, Psyrri A, Keilholz U, Rosenthal D
Oncologist. 2017; 22(7):811-822.
PMID: 28526718
PMC: 5507644.
DOI: 10.1634/theoncologist.2016-0433.
